Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma
Số trang: 7
Loại file: pdf
Dung lượng: 610.90 KB
Lượt xem: 8
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
TP300, a recently developed synthetic camptothecin analogue, is a highly selective topoisomerase I inhibitor. A phase I study showed good safety and tolerability. As camptothecins have proven active in oesophagogastric adenocarcinomas, in this phase II study we assessed the efficacy and safety of TP300 in patients with gastric or gastro-oesophageal junction (GOJ) adenocarcinomas.
Nội dung trích xuất từ tài liệu:
Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma
Nội dung trích xuất từ tài liệu:
Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Topoisomerase-I inhibitor Phase II study Gastro-oesophageal junction adenocarcinoma Safety profile Oesophago-gastric adenocarcinomaTài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 173 0 0 -
6 trang 168 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 145 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 121 0 0 -
12 trang 96 0 0
-
19 trang 75 0 0
-
17 trang 66 0 0
-
9 trang 45 0 0
-
12 trang 39 0 0
-
Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer
17 trang 38 0 0